Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 5NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Central Nervous System Neoplasms 27Astrocytoma 15Oligodendroglioma 14Glioblastoma 14Gliosarcoma 12Glioma 11Brain Neoplasms 11Ependymoma 4Spinal Cord Neoplasms 3Neuroblastoma 3Somatostatinoma 2Neoplasm Metastasis 2Melanoma 2Medulloblastoma 2Lymphoma 2Lung Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Adenoma, Islet Cell 2Sarcoma, Ewing 1Rhabdoid Tumor 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Optic Nerve Glioma 1Neurotoxicity Syndromes 1Neuroectodermal Tumors, Primitive 1Leukemia 1Insulinoma 1Glucagonoma 1Glioma, Subependymal 1Gastrointestinal Stromal Tumors 1Gastrinoma 1

Interventions

Temozolomide 1Etoposide 1Cisplatin 1Carboplatin 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Carcinoma, Neuroendocrine × Temozolomide × Clear all
NCT02595424 2026-05-01

Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
67 enrolled 13 charts
Endocrine

Somatostatinoma, Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon âš¡